In life sciences, patent questions sit directly beside scientific, development, regulatory and commercial decisions. Global Patents is designed to connect those worlds through product-led FTO and IP intelligence.
A therapeutic or biotech product can combine multiple potentially claim-relevant layers—from active modality and target to formulation, delivery, manufacturing and use. Global Patents begins with the product architecture so the patent workflow can reflect the innovation being developed.
The technical feature model determines which patent concepts, classifications and alternatives deserve attention.
Commercial plans turn a global patent landscape into concrete jurisdictional questions that require evidence and professional review.
FTO is not necessarily a single event. Development, filings, competitor activity and patent status can change before commercialization.
The goal is not to replace formal legal review. It is to make structured patent evidence useful earlier and repeatedly as the product evolves.
Structure the invention, technical features and known alternatives.
Connect changing product architecture to relevant patent themes.
Search, triage and iteratively review patent-family evidence.
Organize target-market evidence and unresolved legal questions.
Carry evidence into design, licensing, white-space and monitoring work.
These scenarios illustrate where a product-led FTO intelligence workflow can support teams before qualified professionals make final legal conclusions.
Model claim-relevant features such as modality, antigen or target, formulation, delivery and medical use, then connect them to an explainable search design.
Separate product risk axes so a formulation, carrier or delivery system can be investigated alongside—but not confused with—the active therapeutic concept.
Structure reusable technical features and specific product embodiments so evidence can be reviewed at the appropriate level of technical and commercial relevance.
Organize product, market and patent-family evidence so investors and strategic partners can identify unresolved issues for specialist review.
Global Patents is being developed from Basel—an environment where pharmaceutical, biotechnology, research, investment and professional IP expertise intersect. It provides a focused launch environment for developing the platform with demanding life-science use cases before broader sector expansion.
Develop around real scientific and IP workflows rather than generic AI search.
Engage IP specialists, companies, researchers and strategic capital around the same decision chain.
Use Switzerland as a focused starting point for cross-border patent and innovation intelligence.
Product-led FTO can involve unpublished inventions, technical alternatives, own filings, development stage, market-entry plans and legal strategy. Global Patents therefore treats confidentiality and controlled AI infrastructure as core product requirements.
Sensitive information is handled within protected processing environments.
Customer documents, inventions, searches and case information are not used to train AI models.
Sensitive information is designed to remain segregated across organizations and professional matters.
AI supports evidence work; qualified professionals remain responsible for legal interpretation and final conclusions.
A structured FTO case can become the foundation for recurring monitoring, portfolio intelligence and broader strategic understanding of the innovation landscape.
For biotech and pharma teams, patent professionals, investors and strategic partners.
Discuss a life-science use case →